Resultados: 80

    Guideline No. 450: care of pregnant women living with HIV and interventions to reduce perinatal transmission

    J. obstet. gynaecol. Can; 46 (6), 2024
    This guideline provides an update on the care of pregnant women living with HIV and the prevention of perinatal HIV transmission. This guideline is a revision of the previous guideline, No. 310 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission, a...

    Consolidated guidelines on differentiated HIV testing services

    hese guidelines outline a public health approach to strengthening and expanding HIV testing services (HTS). They present and discuss key updates to WHO guidelines on HTS, with a focus on new evidence, new recommendations, good practices and operational considerations that respond to the changing needs of...

    WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities

    Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. These consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities summarize the latest WHO recommendations on TB and key comorbidities. ...

    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical investigation and management of pyrexia of unknown origin 2023

    Now that the majority of people living with HIV take combination antiretroviral therapy (ART), the spectrum of causes of pyrexia of unknown origin (PUO) has changed compared with the pre-ART era. In these guidelines, we focus on causes and evaluation of PUO among people living with HIV with CD4 counts <3...

    Guidelines on long-acting injectable cabotegravir for HIV prevention

    In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...

    Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact

    As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions. These guidelines focus on the collec...

    Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV

    Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa. These guidelines update the recommendations that were first released in 2018 ...

    WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia 

    The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with Leis...

    Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

    These guidelines provide guidance on the diagnosis of HIV infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 201...